Lumos Diagnostics has increased live FebriDx sites to 215 and moved two additional top 100 US urgent care groups into network rollout across more than 40 sites. Two further health-system-owned groups are validating the test across more than 45 sites, but the announcement does not disclose contract values or guaranteed purchase volumes.
- Live FebriDx sites rise to 215 from 170
- 405 sites are now in clinical and economic evaluation
- Two top 100 urgent care groups enter rollout across 40-plus sites
- Two further groups validate FebriDx across more than 45 sites
- Potential opportunity remains distinct from realised revenue
FebriDx live network reaches 215 sites
Lumos Diagnostics Holdings Ltd (ASX:LDX) is turning a widening US evaluation pipeline into a larger live network, with FebriDx now deployed at 215 sites, up from 170 in July. Sites under active clinical and economic evaluation have also climbed to 405 from 350.
The numbers mark a 26% increase in live sites and a 16% rise in active evaluation sites, based on the company’s disclosed figures. Lumos says the live network spans 26 states and represents an estimated 0.9 million to 1.2 million acute respiratory illness visits a year, although that is a potential patient-volume benchmark rather than a measure of tests sold or revenue generated.
Four health-system accounts advance
Two additional top 100 US urgent care groups, both owned and operated by major health systems, have moved into network rollout. Together, they are expected to deploy FebriDx across more than 40 sites, bringing the product into larger regional and academic healthcare networks that include urgent care, outpatient and hospital services.
Two other top 100 groups are further back in the process, conducting clinical and economic validation across more than 45 sites. Their assessments cover clinical performance, reimbursement, workflow integration and health-economic impact before any broader deployment decision. Lumos’ four-stage framework distinguishes these activities from standardised adoption, where the test becomes embedded in standing orders, triage protocols or routine care pathways.
The company points to its 44-site WellStreet Urgent Care program as the template: an initial pilot expanded across the network, which includes more than 165 sites. That progression is relevant because the current announcement describes account advancement and rollout commitments, not completed conversion of all evaluated locations into routine, repeat ordering.
Pipeline scale still needs to convert into sales
Lumos estimates that the 405 sites under active evaluation could represent 1.6 million to 2.2 million annual acute respiratory illness visits. More than 90% of payments were covered by US reimbursement data reported at 27 July, but the company says reimbursement information will be updated according to formal reporting from Acuity MD.
That leaves the next test relatively clear. Lumos recognises US FebriDx revenue when product ships to exclusive distributor Phase Scientific, so the site counts will matter financially only as they translate into orders, utilisation and repeat adoption. The announcement provides no incremental revenue guidance, contract values or purchase guarantees, while the respiratory season offers a near-term period in which deployment and utilisation may become more visible.
Bottom Line?
The commercial funnel is becoming more substantial, but the key evidence will be whether 405 evaluation sites convert into repeat orders and standardised clinical use.
Questions in the middle?
- How many of the 405 sites under evaluation will progress to network rollout?
- Will the new health-system deployments produce material FebriDx orders during the US respiratory season?
- Can Lumos demonstrate repeat utilisation and standardised adoption beyond initial site deployment?